SignPath gets the go ahead on its curcumin IND


The FDA approves SignPath's (SGTH) IND for curcumin, 99.2% pure synthesized diferuloylmethane as a potential treatment for cancer.

The company plans to initiate a Phase 1 trial in 20 - 24 patients with refractory metastatic or recurrent non-small cell lung cancer. Subjects will receive ascending IV doses of Lipocurc (curcumin) once per week for eight weeks to determine the optimal safe dosage.

In another Phase 1 trial, 9 - 12 patients with progressive Parkinson's disease will receive ascending doses of Lipcurc to determine the optimal safe dosage.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs